CellsBin, a biotechnology company developing technology for rare-cell analysis, has announced the closing of its Series A funding round led by 108 BioCapital. The company did not disclose the amount raised.
CellsBin is developing its Rare-Cell Intelligence Platform, which combines microfluidics, advanced imaging, single-cell analysis and artificial intelligence to detect and study rare cells.
The platform is designed to help researchers and clinicians better understand how cells behave, how diseases develop and why patients can respond differently to cell-based treatments.
“This financing represents an important milestone in our mission to make rare cells visible, measurable and clinically actionable,” said Ali Kabiri, PhD, Co-founder and Chief Executive Officer of CellsBin. “108 BioCapital shares our conviction that rare cells contain critical biological information that can enable earlier, more precise and more confident decisions. This partnership will help us advance the Rare-Cell Intelligence™ Platform, deepen our market and channel reach, and build the capabilities required to establish Rare-Cell Biology™ as a new foundation for understanding disease and therapeutic response.”
CellsBin is initially focusing on cell and gene therapy monitoring and blood cancers. The company aims to expand its technology across drug development, research and clinical medicine.
“CellsBin is building a differentiated platform at the intersection of single-cell biology, artificial intelligence and translational medicine,” said Sasha Bakhru, Managing Partner of 108 BioCapital. “Its ability to detect and characterize extremely rare cells could unlock important insights into therapeutic response, disease progression and patient outcomes. We have been impressed by Ali and the CellsBin team’s scientific rigor, platform vision and commitment to translating complex biology into actionable intelligence.”
“We are excited to partner with CellsBin and support the company as it expands its network of strategic, clinical and commercial relationships,” said Shahryar Oveissi, General Partner of 108 BioCapital. “We are already seeing strong interest from leading healthcare institutions in CellsBin’s technology and its potential to create meaningful clinical impact. We believe the 108 BioCapital ecosystem can help accelerate the company’s next phase of growth.”
The company will use the new funding to increase commercial adoption, develop partnerships, expand research and product development, strengthen clinical evidence and hire more employees across its commercial, scientific and technical teams.
CellsBin said its technology is designed to make rare cells easier to detect, measure and monitor, providing additional biological information that may not be captured through conventional testing methods.
